Inpatient Costs of Treating Patients With COVID-19

Abstract

ImportanceWith more than 6.2 million hospitalizations due to COVID-19 in the US, recognition of the average hospital costs to provide inpatient care during the pandemic is necessary to understanding the national medical resource use and improving public health readiness and related policies.ObjectiveTo examine the mean cost to provide inpatient care to treat COVID-19 and how it varied through the pandemic waves and by important sociodemographic patient characteristics.Design, Setting, and ParticipantsThis cross-sectional study used inpatient-level data from March 1, 2020, to March 31, 2022, extracted from a repository of clinical, administrative, and financial information covering 97% of academic medical centers across the US.Main Outcomes and MeasuresCost to produce care for each stay was calculated using direct hospital costs to provide care adjusted for geographic differences in labor costs using area wage indices.ResultsThe sample included 1 333 404 stays with a primary or secondary COVID-19 diagnosis from 841 hospitals. The cohort included 692 550 (52%) men, with mean (SD) age of 59.2 (17.5) years. The adjusted mean cost of an inpatient stay was $11 275 (95% CI, $11 252-$11 297) overall, increasing from $10 394 (95% CI, $10 228-$10 559) at the end of March 2020 to $13 072 (95% CI, $12 528-$13 617) by the end of March 2022. Patients with specific comorbidities had significantly higher mean costs than their counterparts: those with obesity incurred an additional $2924 in inpatient stay costs, and those with coagulation deficiency incurred an additional $3017 in inpatient stay costs. Stays during which the patient required extracorporeal membrane oxygenation (ECMO) had an adjusted mean cost of $36 484 (95% CI, $34 685-$38 284).Conclusions and RelevanceIn this cross-sectional study, an adjusted mean hospital cost to provide care for patients with COVID-19 increased more than 5 times the rate of medical inflation overall. This appeared to be explained partly by changes in the use of ECMO, which increased over time.

Segregation and the onset of COVID-19 in American cities

“…A SD reduction in exposure segregation reduces by 0.174 (8.77 times 2%, the official rate of COVID-19 cases requesting hospitalization according to WHO) the demand for intensive care units, thus reducing the turnaround of IC units by 6.96% (the average number of ICU in American hospitals is 24 per 100,000 residents according to Weiner-Lastinger et al ., 2022). Despite the obvious life-saving positive impact of reducing segregation, the effect leads to a reduction of financial pressure on hospitals of at least $723 for the average COVID-19 patient treated in IC units (given that the direct cost of COVID-19 inpatient was of $10,394 in 2020, see Kapinos et al ., 2024).…”

Durability of SARS-CoV-2 IgG Antibodies: Insights from a Longitudinal Study, Puerto Rico

“…Treating severe COVID-19 cases is costly, with inpatient stays averaging $11,275 as of March 2022. 55 Widespread vaccination reduces these high-cost hospitalizations, offering clear economic benefits.…”